India markets closed

  • BSE SENSEX

    47,705.80
    -243.62 (-0.51%)
     

  • Nifty 50

    14,296.40
    -63.05 (-0.44%)
     

  • USD/INR

    75.4760
    +0.0360 (+0.05%)
     

  • Dow

    33,935.68
    +114.38 (+0.34%)
     

  • Nasdaq

    13,789.17
    +2.90 (+0.02%)
     

  • BTC-INR

    4,196,563.00
    -18,975.50 (-0.45%)
     

  • CMC Crypto 200

    1,278.53
    +15.57 (+1.23%)
     

  • Hang Seng

    28,621.92
    -513.81 (-1.76%)
     

  • Nikkei

    28,508.55
    -591.83 (-2.03%)
     

  • EUR/INR

    90.6550
    -0.1505 (-0.17%)
     

  • GBP/INR

    104.8734
    -0.2326 (-0.22%)
     

  • AED/INR

    20.5030
    +0.0130 (+0.06%)
     

  • INR/JPY

    1.4298
    -0.0003 (-0.02%)
     

  • SGD/INR

    56.7430
    -0.0090 (-0.02%)
     
DOWNLOAD:

The best finance destination to track markets & economy

Gold Treasure, More Than The GDP Of Many Countries, Found In Turkey

Aditi Gupta
·2-min read

Unexpected gold treasure discoveries are always interesting, but this discovery is rather unique. Recently, Turkey found a colossal amount of gold treasure.

I am using the word “colossal” specifically as the entire gold deposit weighs approximately 99 tonnes or 99,000 kgs and the value of this gold is estimated to be around $6 billion or Rs. 44,000 crore.

Notably, this amount is worth more than the Gross Domestic Product (GDPs) of many countries.

The Discovery

A fertiliser manufacturing company based in Turkey, Gubertas Fertilizer Production Company, discovered this huge heap of gold treasure. The gold treasure was discovered in Sögüt, the central-western region in Turkey.

The information of this discovery was shared by Fahrettin Poyraz, head of the Agricultural Credit Cooperative of the Turkish Gubertas Fertilizer Production Company. The news was further confirmed by Anadolu, a state-run news agency in Turkey.

According to Anadolu, Poyraz said, “We are talking about a value close to six billion dollars.”

Poyraz further added that “Within two years, we will extract the first gold and bring value to the Turkish economy.”

Read More: People In An Andhra Pradesh Village Find Gold Beads On The Beach After Cyclone Nivar

Also, the shares of Gubertas saw an immense increase of 10 per cent on the Turkish stock exchange – Borsa Istanbul, after this news broke.

Countries With Less GDP Than Discovered Gold

As per the latest report by Worldometers, a website providing real-time data on various topics, the tropical paradise Maldives has a GDP of $4.87 billion, West African country Liberia is at $3.29 billion, India’s neighbour Bhutan is at $2.53 billion, and the South African country Lesotho is at $2.58 billion.

Other countries like Mauritania, Montenegro, Barbados, Guyana also have an economy less than the gold treasure discovered in Turkey.

But this is not the first time Turkey has managed to find such a precious and massive treasure. Back in September of this year, Turkey broke all the records by producing 38 tonnes or 38,000 kgs of gold.

And according to Faith Donmez, Turkey’s Minister of Energy and Natural Resource, the country is aiming for an increase in its gold production to 100 tonnes by the next five years.

At this rate, Turkey might one day take over the whole world!

Image Sources: Google Images

Sources: CNBC TV18, Business Today, Zee News

Find the Blogger: @aditi_21gupta

This post is tagged under: Gold treasure, GDP, Turkey, Gross domestic product, Gubertas Fertilizer Production Company, Sögüt, Fahrettin Poyraz, Anadolu, dollars, billions, Borsa Istanbul, gold, Maldives, Worldometers, Liberia, Bhutan, Lesotho, Mauritania, Montenegro, Barbados, Guyana, Faith Donmez, gold production increase

Other Recommendations:

World’s First Hotel To Be Equipped With Gold Plated Bathtub, Toilet Seat, Etc.

Latest stories

  • Dream Industrial REIT Announces April 2021 Monthly Distribution

    DREAM INDUSTRIAL REIT (TSX: DIR.UN) (the "Trust") announced today its April 2021 monthly distribution in the amount of 5.833 cents per Unit (70 cents annualized). The April distribution will be payable on May 14, 2021 to unitholders of record as at April 30, 2021.

  • Greenville-Pitt County ‘Says Yes’ to the Free, At-Home COVID-19 Testing Challenge

    With 12,000 free, rapid test kits already claimed, Pitt County Health Department encourages others to join the testing challenge while supplies last

  • Worldwide Cytogenetics Industry to 2030 - Important Applications Include Drug Discovery and Development of Personalized Medicine - ResearchAndMarkets.com

    The "Cytogenetics - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

  • Delhi HC Serves Contempt Notice to Oxygen Manufacturer

    INOX had failed to comply with the court’s earlier order to supply oxygen to the Delhi government.

  • Hamilton International Returns to Polyester Industrial Yarn Segment

    Effective immediately, Hamilton International is pleased to announce its return as an independent supplier to the polyester industrial yarn segment.

  • Global Electric Vehicle (EV) Battery Housing Market Analysis Report 2021-2025: Focus on Battery Housing Materials, Component, Cell Format, and Application, Supply Chain Analysis - ResearchAndMarkets.com

    The "Electric Vehicle (EV) Battery Housing Market - A Global and Regional Analysis: Focus on Battery Housing Materials, Component, Cell Format, and Application, Supply Chain Analysis, Country Analysis, and Impact of COVID-19 - Analysis and Forecast, 2019-2025" report has been added to ResearchAndMarkets.com's offering.

  • Watch: SRH CEO Kaviya Maran Gets Emotional After Jonny Bairstow’s Six

    SunRisers Hyderabad (SRH) CEO, Kaviya Maran is always involved in her team and she has been one of the most looked out for faces whenever SRH take to the field. Be it in the IPL auction or be it during the tournament, Kaviya Maran makes sure she is there with her side at all times. IPL 2021 didn’t begin on a good note for SunRisers Hyderabad. They lost all three of their opening matches at Chennai and were at the bottom of the IPL 2021 points table when the game against Punjab Kings (PBKS) began on Wednesday. SRH registered their The post Watch: SRH CEO Kaviya Maran Gets Emotional After Jonny Bairstow’s Six appeared first on CricketAddictor.

  • Health Insurance Market Size [2021-2028] | Is set to reach USD 3,038.6 Billion and Exhibit a CAGR of 5.5% by 2028

    Key Prominent Players Covered in the Health Insurance Market are CVS Health Corporation (Aetna health) (Woonsocket, U.S.), Humana Inc (Louisville, U.S.), Centene Corporation (St. Louis, U.S.), Cigna Corporation (Bloomfield, U.S.), United HealthCare Services, Inc (Edina, U.S.), Allianz (Munich, Germany), National Insurance Company Limited. (Kolkata, India), Anthem Health Insurance (Indianapolis, Indiana), WellCare Health Plans, Inc. (Tampa, U.S.), Bupa Global (London, U.K.) and Other PlayersPune, India, April 21, 2021 (GLOBE NEWSWIRE) -- The global “health insurance market” size is set to reach USD 3,038.6 billion by 2028. Fortune Business Insights™ presented this information in a new study, titled, ““Health Insurance Market, 2021-2028.” The study further mentions that the market stood at USD 1,966.6 billion in 2020. It would exhibit a CAGR of 5.5% in the forecast period between 2021-2028. Several government and private agencies are introducing new schemes to attract more customers. In December 2020, for instance, ICICI Lombard unveiled its latest ‘ICICI Lombard Complete Health Insurance’ featuring unique benefits and health plans. Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/sample/health-insurance-market-101985 COVID-19 Pandemic: Relaxations of Premiums May Hamper Growth The COVID-19 pandemic has compelled various companies to strengthen their existing schemes for meeting the high demand. They have started introducing new subscriptions including COVID-19 protection coverage. But, a few authorities declared relaxations of premiums for a short duration. It may affect growth negatively in the near future. We are offering authentic research reports to help you overcome this grave situation. To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/health-insurance-market-101985 Report Coverage- The report provides intelligent insights on new product developments, R&D activities, and future technologies. At the same time, it delivers elaborate information about recent investments, developments, and untapped geographies. Besides, our analysts have conducted an assessment of manufacturing capabilities, strategies, and shares of renowned players. Quick Buy – Health Insurance Market https://www.fortunebusinessinsights.com/checkout-page/101985 Drivers & Restraints- Emergence of Unique Healthcare Plans by Firms to Bolster Growth The rising launch of state-of-the-art smartphone apps and new insurance schemes by various prominent companies would contribute to the market growth in the near future. Allianz Care, for instance, introduced its new suite of private health insurance plans in November 2019. These were specially developed for modern families. The new offering provides families, couples, and private individuals more control over their international healthcare policy. Similarly, in February 2021, Bharti AXA General Insurance launched a new healthcare offering named Health AdvantEDGE to deliver holistic protection against high expenses associated with medical emergencies amid COVID-19. However, strict norms governing the verification of plans to prevent fraudulent insurance claims may hinder growth. Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/health-insurance-market-101985 Segmentation- Private Providers Segment to Dominate Backed by Their Increasing Presence Based on end-users, the market is divided into individuals and corporates. By the network provider, it is segmented into provider organizations (PPOs), point of services (POS), health maintenance organization (HMOs), and exclusive provider organizations (EPOs). Based on insurance type, it is segregated into medical insurance, critical illness insurance, and others. Here’s a brief note of the service provider criterion: By Service Provider: The market is bifurcated into private providers and public providers. Amongst them, the private providers segment is expected to dominate in terms of the health insurance market share throughout the forthcoming years. This growth is attributable to the surging entrance of these providers in developing economies worldwide. Regional Insights- Rising Prevalence of Chronic Disorders to Propel Growth in Asia Pacific North America: The market in this region stood at USD 953.7 billion in 2020. It is likely to remain in the leading position in the upcoming years backed by the expensive nature of medical products. At the same time, the increasing population opting for various health insurance policies would aid regional growth.Europe: Europe will remain in the second position because of the increasing awareness of the benefits of possessing health insurance plans. Also, governments of several European countries have made it mandatory for citizens to have at least one insurance policy.Asia Pacific: The region is expected to grow rapidly over the forecast period on account of the surging cases of chronic diseases and increasing population in developing countries, such as India and China. Competitive Landscape- Mergers & Acquisitions to Be the Vital Strategy of Key Companies The global market houses several renowned companies, such as Cigna Corporation, Centene Corporation, and United HealthCare Services, Inc. They are mainly striving to adopt the strategy of merger and acquisition to cater to the high demand. Below is one of the latest industry developments: November 2018: Aetna and CVS Health closed the merger of USD 69 billion. This would blend the former’s insurance business with the latter’s pharmacies. Both companies aim to simplify how customers access healthcare by making it cost-effective. Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/health-insurance-market-101985 A list of reputed health insurance companies operating in the global market: CVS Health Corporation (Aetna health) (Woonsocket, U.S.)Humana Inc (Louisville, U.S.)Centene Corporation (St. Louis, U.S.)Cigna Corporation (Bloomfield, U.S.)United HealthCare Services, Inc (Edina, U.S.)Allianz (Munich, Germany)National Insurance Company Limited. (Kolkata, India)Anthem Health Insurance (Indianapolis, Indiana)WellCare Health Plans, Inc. (Tampa, U.S.)Bupa Global (London, U.K.)Other Players Table of Content Introduction Research ScopeMarket SegmentationResearch MethodologyDefinitions and Assumptions Executive SummaryMarket Dynamics Market DriversMarket RestraintsMarket Opportunities Key Insights Prevalence of Key Disease Conditions, Key Countries, 2019Technology Advances, Health InsuranceNew Product Launches, Key PlayersKey Developments, Mergers, Acquisitions, etc.Impact of Covid-19 on the Market ToC Continue… Have a Look at Related Reports: Europe Compression Bandages Market Size, Share & Industry Analysis, By Product (Short Stretch Bandages, Long Stretch Bandages, Multilayer Compression Bandages), By Material (Polyster, Latex, Cotton, Others), By Application (Wound Management, Deep Vein Thrombosis, Lymphedema, Others), By End-user (Hospitals & Ambulatory Surgical Centers, Clinics, Nursing Care Centers & Skilled Nursing Facilities, Home Care, Others), and Regional Forecast 2019 – 2026 Sharps Containers Market Size, Share & Industry Analysis, By Product Type (Multipurpose Containers, Patient Room Containers, Phlebotomy Containers), By Waste Generators (Hospitals, Pharmacies, Academic & Research Institutes, Others), By Usage (Reusable Containers and Single-Use Containers), By Waste Type (Sharps Waste, Infectious Waste), By Size (1–2 Gallons, 2–4 Gallons, 4–8 Gallons Others) and Regional Forecast, 2019 – 2026 Germany Pneumococcal Vaccines market Size, Share & Industry Analysis, By Product Type (PCV10, PCV13, and PPSV23), By End User (Hospitals, Clinics, and Others) and Region Forecast, 2019-2026 Diabetic Foot Ulcer Treatment market Size, Share & Covid-19 Impact Analysis, By Ulcer Type (Neuropathic Ulcer, Ischemic Ulcer, Neuro-ischemic Ulcer), By Product (Wound-care Dressings, Wound-care Devices, Active Therapies, and Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Homecare Settings), and Regional Forecast, 2020-2027 About Us: Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges. Contact Us: Fortune Business Insights™ Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India. Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email:sales@fortunebusinessinsights.com LinkedIn | Twitter | Blogs

  • Global Robotic Surgery Devices Market (2020 to 2023) - Opportunities and Strategies with COVID-19 Growth and Change - ResearchAndMarkets.com

    The "Robotic Surgery Devices Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

  • Concerns grow for three missing teenagers as police launch urgent appeal to find them

    Leona Derbyshire, Matej Bulander and Allyx Queen were last seen in Chorley at around 8.30pm on Tuesday night.

  • This eco-friendly, high-speed charger will be your constant outdoor companion—and it’s 25 percent off

    Your purchase of the pocket-sized Nimble Eco-Friendly CHAMP 10k PD Portable Charger helps keep 400 million tons of plastic out of landfills each year.

  • Pakistan holds on to win 1st T20 vs. Zimbabwe

    Pakistan held on to win the first Twenty20 against Zimbabwe on Wednesday by managing to defend a modest total of 149-7. Zimbabwe only got 138-7 in reply after Usman Qadir's 3-29 thwarted the home team at Harare Sports Club and gave Pakistan an 11-run victory. Opener Mohammad Rizwan batted through the Pakistan innings for his 82 not out from 61 balls.

  • Airlines cut global traffic forecast on recovery setbacks

    Air traffic will recover more slowly than previously expected from the COVID-19 pandemic, as vaccination delays and government "risk aversion" slows the reopening of routes, global airlines body IATA said on Wednesday. Global traffic this year will amount to 43% of pre-crisis levels based on passenger numbers and distance flown, the International Air Transport Association said, below the 51% it had forecast late last year. "This crisis is longer and deeper than anyone could have expected," Director General Willie Walsh said.

  • 5 genius accessories to make your phone more earth-friendly — all 25 percent off!

    Did you know the carbon footprint of a cell phone is 154 pounds? The power to reduce that number is in your hands.

  • COVID impact: Bank unions urge IBA for restriction in services, cutting public dealing hours

    New Delhi, Apr 21 (PTI) With COVID-19 cases surging across the country, bank unions have requested industry body IBA for restriction in services and reduction in public dealing time to around 3 hours per day till the situation improves to protect bank employees from the coronavirus infection.

  • Global Tissue Engineering Market to Reach $26.8 Billion by 2027

    Abstract: - Global Tissue Engineering Market to Reach $26. 8 Billion by 2027. - Amid the COVID-19 crisis, the global market for Tissue Engineering estimated at US$11 Billion in the year 2020, is projected to reach a revised size of US$26.New York, April 21, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Tissue Engineering Industry" - https://www.reportlinker.com/p06033135/?utm_source=GNW 8 Billion by 2027, growing at a CAGR of 13.5% over the analysis period 2020-2027. Orthopedics, Musculoskeletal & Spine, one of the segments analyzed in the report, is projected to record a 12.1% CAGR and reach US$6.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cardiology & Vascular segment is readjusted to a revised 15.7% CAGR for the next 7-year period. - The U.S. Market is Estimated at $3.3 Billion, While China is Forecast to Grow at 13.1% CAGR - The Tissue Engineering market in the U.S. is estimated at US$3.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.7 Billion by the year 2027 trailing a CAGR of 13.1% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.7% and 11.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10% CAGR. - Cord Blood & Cell Banking Segment to Record 14.7% CAGR - In the global Cord Blood & Cell Banking segment, USA, Canada, Japan, China and Europe will drive the 14.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.5 Billion in the year 2020 will reach a projected size of US$4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3.2 Billion by the year 2027. - Select Competitors (Total 33 Featured) - Acelity L.P. Inc.Advanced Cell TechnologyAllergan PlcArteriocyteAthersysBaxter International IncBioMimetic TherapeuticsCook Biotech Inc.CryoLifeDePuy Synthes (Johnson & Johnson Services, Inc.)Integra Life Sciences CorporationLifeCell Kinetic ConceptsMedtronicOrganogenesis Inc.RTI surgicalSanofiStemCells, Inc.Stryker CorporationZimmer Biomet Read the full report: https://www.reportlinker.com/p06033135/?utm_source=GNW I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Tissue Engineering by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 2: World 7-Year Perspective for Tissue Engineering by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 Table 3: World Current & Future Analysis for Orthopedics, Musculoskeletal & Spine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 4: World 7-Year Perspective for Orthopedics, Musculoskeletal & Spine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 5: World Current & Future Analysis for Cardiology & Vascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 6: World 7-Year Perspective for Cardiology & Vascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 7: World Current & Future Analysis for Cord Blood & Cell Banking by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 8: World 7-Year Perspective for Cord Blood & Cell Banking by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 9: World Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 10: World 7-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 11: World Current & Future Analysis for Gastrointestinal & Gynecology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 12: World 7-Year Perspective for Gastrointestinal & Gynecology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 Table 13: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 14: World 7-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Table 15: USA Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 16: USA 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 CANADA Table 17: Canada Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 18: Canada 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 JAPAN Table 19: Japan Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 20: Japan 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 CHINA Table 21: China Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 22: China 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 EUROPE Table 23: Europe Current & Future Analysis for Tissue Engineering by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 24: Europe 7-Year Perspective for Tissue Engineering by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 Table 25: Europe Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 26: Europe 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 FRANCE Table 27: France Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 28: France 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 GERMANY Table 29: Germany Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 30: Germany 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 ITALY Table 31: Italy Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 32: Italy 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 UNITED KINGDOM Table 33: UK Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 34: UK 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 REST OF EUROPE Table 35: Rest of Europe Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 36: Rest of Europe 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 ASIA-PACIFIC Table 37: Asia-Pacific Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 38: Asia-Pacific 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 REST OF WORLD Table 39: Rest of World Current & Future Analysis for Tissue Engineering by Application - Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 40: Rest of World 7-Year Perspective for Tissue Engineering by Application - Percentage Breakdown of Value Sales for Orthopedics, Musculoskeletal & Spine, Cardiology & Vascular, Cord Blood & Cell Banking, Cancer, Gastrointestinal & Gynecology and Other Applications for the Years 2020 & 2027 IV. COMPETITION Total Companies Profiled: 33Read the full report: https://www.reportlinker.com/p06033135/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

  • Novo Nordisk to initiate phase 3a development in obesity with oral semaglutide

    Bagsværd, Denmark, 21 April 2021 – Novo Nordisk today announced the decision to enter phase 3a development in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a clinical programme with once-weekly subcutaneous (sc) semaglutide 2.4 mg. Novo Nordisk intends to initiate a pivotal phase 3a programme with approximately 1,000 people with obesity or overweight with comorbidities. The global 68-week trial is planned for initiation in the second half of 2021 and will investigate the efficacy and safety of oral semaglutide compared to placebo. “There is a significant unmet medical need within obesity treatment today. With oral semaglutide we aim to introduce a convenient and effective treatment option for people with obesity and healthcare providers enabling broader use of anti-obesity medication,” said Martin Holst Lange, executive vice president, Development at Novo Nordisk. “As a complement to our injectable anti-obesity medications, oral semaglutide has the potential to help more people living with obesity achieve weight loss goals and improve their health.” About obesityObesity is a chronic disease that requires long-term management. It is associated with many serious health complications and decreased life expectancy. Obesity-related complications are numerous and include type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, non-alcoholic fatty liver disease and certain types of cancer. The current COVID-19 pandemic has shown that obesity also increases the risk of severe illness and hospitalisation due to COVID-19. The global increase in the prevalence of obesity is a public health issue that has severe cost implications to healthcare systems. Approximately 650 million adults are estimated to live with obesity worldwide. About semaglutide 2.4 mg for weight management and STEPOnce-weekly sc semaglutide 2.4 mg is currently under regulatory review in the US and the EU as a treatment for adults with obesity. Semaglutide is an analogue of the human glucagon-like peptide-1 (GLP-1) hormone. It induces weight loss by reducing hunger, increasing feeling of fullness and thereby helping people eat less and reduce their calorie intake. The submissions for regulatory review are based on the results from the STEP (Semaglutide Treatment Effect in People with obesity) phase 3 clinical development programme. The global clinical phase 3a programme consisted of four trials and enrolled approximately 4,500 adults with overweight or obesity. About oral semaglutideOral semaglutide (7 mg and 14 mg) is approved as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes in the US, EU and Japan under the trade name, Rybelsus®. The approval of Rybelsus® is based on the results from 10 clinical trials which included 9,543 adults with type 2 diabetes. Rybelsus® demonstrated a safe and well-tolerated profile across the clinical trials, with the most common adverse event being mild to moderate nausea which diminished over time. About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 45,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Media: Mette Kruse Danielsen+45 3079 3883mkd@novonordisk.comMichael Bachner (US)+1 609 664 7308mzyb@novonordisk.com Investors: Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.comValdemar Borum Svarrer+45 3079 0301jvls@novonordisk.comAnn Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.comMark Joseph Root+45 3079 4211mjhr@novonordisk.comKristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com Company announcement No 25 / 2021 Attachment PR210421_Oral_obesity_initiation

  • Economic outlook: 'The market is realizing it's got some hard work to do'

    Yahoo Finance’s Myles Udland, Brian Sozzi, and Julie Hyman break down the stock market action and outlook with Jim Caron, Morgan Stanley Investment Management Fixed Income Portfolio Manager.

  • Ruth Dodsworth says she 'wouldn't be here now' without children's warning over abusive ex-husband

    The ITV weather presenter's children had told their mother 'he's going to kill you'.

  • UPDATE 7 - Notice Regarding the Semiconductor Manufacturing Factory (Naka Factory) Fire

    Renesas Electronics Corporation (TSE:6723), a premier supplier of advanced semiconductor solutions, today confirmed the emission of smoke at 16:29 JST from the power panel of a Rail Guided Vehicle (RGV) located on the basement of the N3 Building (300mm line) of Naka Factory. The smoke was extinguished immediately by Renesas employees after it began. Following the confirmation of the site by the fire department and maintenance of the power panel, which was the cause of the smoke, production has been resumed as of 20:00 JST on the first floor and the second floor of the N3 Building. There are no impacts to the production and shipment outlook announced in "UPDATE 6 - Notice Regarding the Semiconductor Manufacturing Factory (Naka Factory) Fire". We also confirmed no casualties from this incident.